ページ8 - 最高の医師 - トップ672名の医師

アスクレピオス・バルムベック病院乳腺病理センター長のシュルツ私講師医学博士は、ハンブルクにおける乳癌患者の4人に1人を診療しています。治療は最新の臨床基準に準拠しています。

アスクレピオス・バルムベック病院の乳腺センターは、FOCUS誌により5年連続でドイツ最優秀施設の一つに選出されています。この評価は乳癌治療に関するものです。

シュルツ私講師医学博士および副センター長のホッフェレ医学博士は、毎月50名以上の患者に手術を行っています。

Dr. Sefik Igdem is a respected radiation oncologist with 37 years of experience. He is known for his skill in advanced cancer treatments. Dr. Igdem specializes in radiotherapy, intensity-modulated radiation therapy, 3D conformal radiation therapy, and image-guided radiotherapy. He focuses mainly on prostate cancer and head and neck cancers.

Dr. Igdem has played a key role in bringing new technologies and conformal treatments to radiation oncology. He has also completed a retrospective analysis of 600 postmenopausal breast cancer cases. This work shows his commitment to evidence-based care. His broad clinical experience and focus on innovation have made him a leader in his field.

この医師は39年の経験を持つ核医学専門医であり、現在はMedipol Mega University Hospitalで診療を行っています。この医師はGazi Universityで教授職を務め、Ankara Order Laboratoryの核医学部門のディレクターを務めました。この医師はトルコ核医学協会およびヨーロッパ核医学協会のメンバーです。この医師は1984年にErciyes University Faculty of Medicineを卒業し、1992年にAnkara Universityで核医学専門医となりました。

Education:

Teaching course on “Lymphatic mapping and sentinel node”

June 1998, MDA Cancer Center, Houston, Texas, USA

General Surgery

Feb. 1993 – Dec. 1996, Şişli Etfal Hospital, Istanbul, Turkey

General Surgery

May 1990 – Jan. 1993, Lille University Hospital, Lille, France 

M.D.

1983 – 1990, Cerrahpasa School of Medicine, Istanbul, Turkey

Experience

Attending General Surgeon, Jan. 1998 – present 

F.N. Metropolitan Hospital, Istanbul, Turkey

American Cancer Center, Breast Surgery

Attending General Surgeon, 1996 – present 

Medmar Diagnostic Center, Istanbul, Turkey

Diagnosis and monitoring with sophisticated techniques 

General Surgeon, 1996 – 1998

Guzelbahce Medical Center and Yeditepe Hospital, Istanbul, Turkey

Specializing in breast and thyroid surgery

この医師は、脳および脊髄腫瘍の治療に焦点を当てた非常に経験豊富な神経腫瘍学者です。彼女は1996年から1998年までMemorial Sloan-Kettering Cancer Centerで神経腫瘍学の訓練を修了しました。1998年以降、彼女はシニア神経腫瘍学者として勤務し、広範な臨床専門知識を示しています。彼女は1998年から2005年までユタ大学のHuntsman Cancer Instituteで神経腫瘍学サービスのディレクターを務め、神経腫瘍学的ケアの進展を主導しました。<\/p>

エルケ・イェーガー教授は1,100件以上の腫瘍科手術を執刀しており、フォーカス誌によってドイツトップクラスの腫瘍専門医として継続的に評価されています。

• ノルトヴェスト病院 腫瘍内科・血液内科部長
• 肉腫治療および個別化抗腫瘍ワクチンを専門とする
• ゲーテ大学 集学的腫瘍学教授
• 欧州がん研究治療機構（EORTC）会員

約1万件の凍結手術を実施 – 牛立志教授がFudaがんセンターの低侵襲腫瘍治療プログラムを主導。

• Fudaがんセンター院長および外科部長として30年の経験年以上の経験
• がん治療における凍結手術およびナノナイフ手術のパイオニア
• アジア凍結手術学会および国際凍結手術学会の副会長
• 外科腫瘍学的手技に関する100本以上の研究論文を執筆

Head of Neurooncology Clinic of Ichilov

Dr. Michael Shapira is an experienced Bone Marrow Transplantation specialist, who speaks English and Hebrew, and graduated from the Hebrew university medical school in 1999.

• Specializes in Bone Marrow Transplantation
• Speaks English and Hebrew
• Graduated from Hebrew university medical school in 1999
• Specialized in internal medicine in Hadassah medical center
• Joined Bone Marrow Transplantation department in Hadassah as a senior physician

• 2021 - Currently, Istanbul/Turkey
  MEMORIAL ŞİŞLİ HOSPITAL
  Dermatology Specialist
• 2021 - Currently, Istanbul/Turkey
  MEMORIAL ATAŞEHİR HOSPITAL
  Dermatology Specialist
• 2013 - 2021, Istanbul/Turkey
  MEDENİYET UNIVERSITY
  Lecturer
• 2013 - 2016, Istanbul/Turkey
  MEDENİYET UNIVERSITY
  Head of Department
• 2013 - 2014, Istanbul/Turkey
  MEDENİYET UNIVERSITY
  Director of the Institute of Health Sciences
• 2012 - 2012, /ABD
  PITTSBURGH UNIVERSITY
  Visiting Scholar
• 2010 - 2013, Erzurum/Turkey
  ATATURK UNIVERSITY MEDICAL FACULTY
  Professor, Lecturer, Dermatology Specialist
• 2001 - 2007, Van/Turkey
  YUZUNCU YIL UNIVERSITY
  Assistant Professor, Dermatology Specialist

• 2019 - Currently, Istanbul/Turkey
  MEMORIAL ATAŞEHİR HOSPITAL
  Obstetrician and Gynecologist - Gynecological Oncology Surgery
• 2017 - 2019, Istanbul/Turkey
  ISTANBUL MEDENIYET UNIVERSITY GÖZTEPE TRAINING AND RESEARCH HOSPITAL
  Gynecological Oncology Surgery Center
• 2012 - 2017, Istanbul/Turkey
  ZEYNEP KAMIL WOMEN HEALTH AND PEDIATRICS TRAINING AND RESEARCH HOSPITAL
  Gynecology and Obstetrics Specialist
• 2008 - 2012, Bursa/Turkey
  MUSTAFAKEMALPAŞA PUBLIC HOSPITAL
  Gynecology and Obstetrics Specialist
• 2004 - 2008, Erzincan/Turkey
  ERZINCAN PUBLIC HOSPITAL
  Gynecology and Obstetrics Specialist

41年の経験 低侵襲消化器内視鏡手術を専門とし、Dr. Rosenはウィーナー・プリヴァートクリニックにて外科的精度と内科的専門知識を融合させた診療を行っています。

• 複雑症例における診断・治療的内視鏡検査の専門家
• オーストリアにおける現代的内視鏡外科手技の先駆者
• 迅速な回復を目的とした低侵襲治療に注力
• 消化器悪性腫瘍および肝疾患を専門とする

Education and Specialization

2017 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine

19 November 2020 Istanbul University Istanbul Faculty of Medicine, Department of Medical Oncology

2011-25 June 2015 Hospitals / Istanbul Haydarpasa Numune Education and Research Hospital

2004 Mersin University Faculty of Medicine

Experience

13.11.2017-29.03.2021 Istanbul University Istanbul Faculty of Medicine Internal Medicine Departments, Department of Internal Medicine

21.03.2011-25.06.2015 Istanbul Haydarpasa Numune Education and Research Hospital



Ferhatoğlu Ferhat, Çağatay Tulin, Okumuş Nigar Gülfer, Aydıner Adnan, Paksoy Nail, Ak Naziye, Aydın Esra, Saip Pinar Mualla (2023). Laterality Of Adrenal Gland Metastasis In Lung Cancer: Results Of A Comparative Study. Eurasian Journal Of Medical Investigatin, 7(2), 101-106., Doi: 10.14744/Ejmi.2023.58954

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

TAŞTEKİN DİDEM, PAKSOY NAİL, DOĞAN İZZET, FERHATOĞLU FERHAT, KHANMAMMADOV NIJAT, BOZBEY HAMZA UGUR, KARABULUT SENEM (2023). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first?line treatment of metastatic gastric cancer: A single?center experience. Journal of Cancer Research and Therapeutics, 19(2), 253-258., Doi: 10.4103/jcrt.jcrt_672_22 (Quarterly=Q4)

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

FERHATOĞLU FERHAT, AYDINER ADNAN, PAKSOY NAİL (2022). Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer. Journal of Surgery and Medicine, 6(12), 986-990., doi: 10.28982/josam.7610

FERHATOĞLU FERHAT, ERTÜRK KAYHAN, TAŞ FARUK (2022). Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences. Journal of Cancer Research and Therapeutics, 0, Doi: 10.4103/jcrt.jcrt_815_21

ÖZGÜR EMRE, FERHATOĞLU FERHAT, ŞEN FATMA, GEZER UĞUR (2022). Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast Cancer. BALKAN MEDICAL JOURNAL, 39(6), 450-451., Doi: 10.4274/balkanmedj.galenos.2022.2022-5-18

Articles

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates. JOURNAL OF COSMETIC DERMATOLOGY, 21(4), 1570-1573., Doi: 10.1111/jocd.14278

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis. Indian Journal of Surgery, Doi: 10.1007/s12262-022-03532-y

DOĞAN İZZET, GÜRBÜZ MUSTAFA, PAKSOY NAİL, FERHATOĞLU FERHAT, VATANSEVER SEZAİ, SAİP PINAR, DEMİRKAZIK AHMET, AYDINER ADNAN (2022). Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine, 101(34), 30188, Doi: 10.1097/MD.0000000000030188

PAKSOY NAİL, KHANMAMMADOV NIJAT, DOĞAN İZZET, FERHATOĞLU FERHAT, YILDIZ ANIL, AK NAZİYE, AYDINER ADNAN (2022). Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study. Medicine, 101(45), 31726, Doi: 10.1097/MD.0000000000031726

PAKSOY NAİL, FERHATOĞLU FERHAT, DOĞAN İZZET, KHANMAMMADOV NIJAT, İRİBAŞ ÇELİK AYÇA, GÜLBAŞ ZAFER, BAŞARAN MERT (2022). High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience. Medicine, 101(49), 32213, Doi: 10.1097/MD.0000000000032213

ÇİL İBRAHİM, KÜÇÜKARDA AHMET, ATCI MUHAMMED MUSTAFA, SECMELER SABAN, PAKSOY NAİL, FERHATOĞLU FERHAT, AK NAZİYE, AYHAN MURAT, TATAROĞLU ÖZYÜKSELER DENİZ, ÖNDER ARİF HAKAN, AVCI OKAN, OYMAN ABDİLKERİM, OKTEN ILKER NIHAT, GÜLTÜRK İLKAY, AKAGÜNDÜZ BARAN, BASOĞLU TÜYLÜ TUĞBA, ÇAKIR EMRE, HACIBEKİROĞLU İLHAN, ÖZÇELİK MELİKE, AYDINER ADNAN (2022). Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori Journal, 108(1), 19-25., Doi: 10.1177/03008916211037739

DOĞAN İZZET, KARABULUT SENEM, TAŞTEKİN DİDEM, FERHATOĞLU FERHAT, PAKSOY NAİL, ŞAKAR BURAK (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. Journal of the College of Physicians and Surgeons Pakistan, 32(8), 1014-1019., Doi: 10.29271/jcpsp.2022.08.1014

FERHATOĞLU FERHAT, TUĞCU MURAT, APAYDIN SÜHEYLA (2022). Factors Affecting Postoperative Morbidity and Mortality in Chronic Hemodialysis Patients. Eurasian Journal of Medical Advances, 2(3), 30-38., doi: 10.14744/ejma.2022.43153

KAPAĞAN TANJU, FERHATOĞLU FERHAT, RETIRED SELİNAY, KILIÇ ÇAĞLA ECEM (2022). Risk Factors for Cutaneous Melanomas and Level of Awareness in Society. Journal of the Turkish Academy of Dermatology, 16(4), 94-100., Doi: 10.4274/jtad.galenos.2022.30092

FERHATOĞLU FERHAT, ALTAN FERHATOĞLU ZEYNEP (2022). Frequency, Demographic and Clinicopathological Characteristics of Skin Cancer Patients Treated and Followed Up in the Medical Oncology Outpatient Clinic. Journal of the Turkish Academy of Dermatology, 16(4), 77-81., Doi: 10.4274/jtad.galenos.2022.04706

KARABULUT SENEM, DOĞAN İZZET, USUL AFŞAR ÇİĞDEM, KARABULUT MEHMET, KARAMAN ŞULE, FERHATOĞLU FERHAT, TAŞTEKİN DİDEM (2021). Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 27(6), 1357- 1363., Doi: 10.1177/1078155220959427

AK NAZİYE, ÖZKAN BERKER, YENİGÜN BÜLENT MUSTAFA, YILMAZBAYHAN EMİNE DİLEK, TOKER SEYFİ ALPER, FERHATOĞLU FERHAT, YAŞAR HATIME ARZU, DİZBAY SAK SERPİL, TANJU SERHAT, DILEGE MUSTAFA ŞÜKRÜ, ERUS SUAT, BULUTAY PINAR, FIRAT PINAR, MANDEL NİL MOLİNAS, KILIÇKAP SAADETTİN, ONDER SEVGEN, DİKMEN ERKAN, ALAN ÖZKAN, YUMUK PERRAN FULDEN, BOZKURTLAR EMİNE, LAÇİN TUNÇ, YILDIZELİ BEDRETTİN, ÖZTÜRK AKIN, KOCATÜRK CELALETTİN İBRAHİM, KARAPINAR KEMAL, ÜRER HALIDE NUR, OYAN ULUÇ BAŞAK, AYDINER ADNAN, DEMİRKAZIK AHMET, ERALP YEŞİM (2021). The role of adjuvant chemotherapy in resected stage I non-small cell lung cancer: A Turkish Oncology Group Study.. Journal of BUON, 26(3), 819-829.

AK NAZİYE, TOKER SEYFİ ALPER, KARA MURAT, ÖZKAN BERKER, ÜLKER MELİKE GÜLER, KABA ERKAN, YEGEN GÜLÇİN, KARAMAN ŞULE, DAĞOĞLU SAKİN RABİA NERGİZ, KAYTAN SAGLAM ESRA, ORAL ETHEM NEZİH, KİZİR AHMET, BAYRAKTAR SOLEY, DİSTÇİ RIAN, FERHATOĞLU FERHAT, AYDIN ESRA, VATANSEVER SEZAİ, ERALP YEŞİM, AYDINER ADNAN (2021). Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center. TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 29(4), 487- 495., Doi: 10.5606/tgkdc.dergisi.2021.20529

AK NAZİYE, PAKSOY NAİL, FERHATOĞLU FERHAT, AYDIN ESRA, DOĞAN İZZET, BEKTAŞ ERDEM, KARACA MERT, OGUZ SOYDİNÇ HİLAL, MINARECİ YAĞMUR, SÖZEN HAMDULLAH, TOPUZ SAMET, SAİP PINAR MUALLA, VATANSEVER SEZAİ (2021). Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma. TURKISH JOURNAL of ONCOLOGY, 36(4), 438-445., Doi: 10.5505/tjo.2021.2882

Director of Radiotherapy Institute Oncology Division

メフメット・ファイク・チェティンダğ博士は、30年以上にわたる実践を経て、腫瘍学の分野で専門家としての地位を確立しています。特に、頭頸部癌に焦点を当てた彼の広範な研究と多数の出版物は、この分野に大きな貢献をしています。彼は化学療法、放射線療法、前立腺除去術などの多様な手技を実行する技能を持っています。

教育

• 1984年にハジェッテペ大学で医学の学位を取得しました。
• 1990年にアンカラ訓練研究病院で放射線腫瘍学を専攻。

プロフェッショナルキャリア

• 1990年から1991年にかけて、アンカラ・ヌムネ訓練調査病院に勤務しました。
• 1993年から2009年にかけて、ドクター・アブドゥラフマン・ユルタスラン腫瘍学訓練調査病院で働きました。
• 2010年から2016年にかけて、アンカラ・アタテュルク訓練研究病院のチームに属していました。

出版物と研究

• 国内科学会議で71件、国際科学会議で14件の論文を発表しました。
• 国内雑誌で6件、国際雑誌で22件の記事を執筆。
• 書籍の一章を執筆し、査読付きの出版物が2件あります。

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

教育

1994-1998 - ベラルーシ、グロドノ大学での医学勉強

専門化

2005-2010 - オンコロジー研修、テルアビブ医療センター、イチロブ

2000-2004 - 第10内科部門での研修、テルアビブ医療センター、イチロブ

1994-1995 - モジル医療センターでの研修、ベラルーシ

認められた専門知識

内科

腫瘍学

臨床経験

2015年から - 腫瘍入院のディレクター、テルアビブ医療センター、イチロブ

2005-2010 - 腫瘍学研修、テルアビブ医療センター、イチロブ

2000-2004 - 第10内科部門での研修、テルアビブ医療センター、イチロブ

2005年から - 腫瘍学における第1、第2、第3相臨床試験の主要研究者および副研究者

2000年1月 - イスラエルでの医師免許取得

1996-1998 - 一般開業医、モジル医療センター、ベラルーシ

1994-1995 - モジル医療センターでの研修、ベラルーシ

EXPERIENCE

2024 - Present, Istanbul, Turkey

MEMORIAL ATAŞEHİR HOSPITAL

Medical Oncology Specialist

2016 - 2024, Istanbul, Turkey

MARMARA UNIVERSITY PENDIK TRAINING AND RESEARCH HOSPITAL

2015 - 2016, Kocaeli, Turkey

KOCAELİ STATE HOSPITAL

Compulsory Service

2011 - 2014, Istanbul, Turkey

DR. LÜTFİ KIRDAR TRAINING AND RESEARCH HOSPITAL

2010 - 2011, Sinop, Turkey

SİNOP DURAĞAN STATE HOSPITAL

Compulsory Service

2004 - 2010, Istanbul, Turkey

ISTANBUL UNIVERSITY CERRAHPAŞA FACULTY OF MEDICINE

EDUCATION

2020 - Present

Marmara University Pendik Training and Research Hospital

Associate Professorship in Medical Oncology

2011 - 2014, Istanbul, Turkey

Dr. Lütfi Kırdar Training and Research Hospital

Medical Oncology Specialization

2004 - 2010, Istanbul, Turkey

Istanbul University Cerrahpaşa Faculty of Medicine

Internal Medicine Specialization

1997 - 2003, Istanbul, Turkey

Istanbul University Cerrahpaşa Faculty of Medicine

Medical Education

SCIENTIFIC PUBLICATIONS

• 63 articles published in journals indexed in international databases (first author in 11 of them).

• Over 100 presentations at international and national congresses.

• 4 review articles published in national journals (first author in 3 of them).

• Authorship of 1 book chapter and co-editorship of 1 book.

シュロミー・コンスタンティーニ教授は、イスラエルで最も優れた脳神経外科医の一人です。彼は、成人と子供の神経外科的ケアの専門家です。コンスタンティーニ教授はイスラエルのハダサ医科大学を卒業し、以下の訓練を受けました：

• 海馬電気生理学（デンマーク）
• テント上腫瘍（ポーランド）
• テント下腫瘍（オランダ）
• マイクロニューロサージェリー（スイス）
• 高度な神経内視鏡（ドイツ）。

専門

医師の専門は、一般および小児脳神経外科です。彼は、子供の脳および脊髄腫瘍の治療を提供し、骨構造に関する先天性および新生児の障害に取り組んでいます。シュロミー・コンスタンティーニ教授は、微細手術、再建的介入、脳血管瘤の外科的修正の専門家です。

受賞歴

• 頭蓋内圧測定に関する研究のための学部賞
• 研究のためのレオ・ダビドフ賞
• アメリカ神経外科医協会（AANS）のマハリー最優秀臨床研究賞。

科学活動

コンスタンティーニ博士は、神経内視鏡、脳研究、および小児脳偶発腫瘍に関する研究活動を行っています。

組織での会員

• イスラエルの脳神経外科学会
• 神経外科医会議（CNS）
• アメリカ神経外科医協会（AANS）
• ヨーロッパ小児神経外科学会（ESPN）
• 国際神経内視鏡学連合（IFNE）
• ヨーロッパ神経外科学会（EANS）
• 国際小児神経外科学会（ISPN）。